At a glance
- Originator UCB
- Class Antihyperlipidaemics; Vasodilators
- Mechanism of Action Cholesterol synthesis inhibitors; Thromboxane receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Ischaemic heart disorders; Thrombosis
Most Recent Events
- 31 Dec 2002 Discontinued - Preclinical for Atherosclerosis in Belgium (unspecified route)
- 31 Dec 2002 Discontinued - Preclinical for Ischaemic heart disorders in Belgium (unspecified route)
- 31 Dec 2002 Discontinued - Preclinical for Thrombosis in Belgium (unspecified route)